Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and suppresses the activity of KRAS G12C mutant proteins, thereby inhibiting KRAS G12C-dependent signaling pathways. Glecirasib exhibits high selectivity, potent inhibition, and favorable safety, and is primarily used in studies of non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
Molekulargewicht:
640.03
Reinheit:
99.70%
CAS Nummer:
[2657613-87-9]
Formel:
C31H26ClF4N7O2
Target-Kategorie:
Ras|||Kras
T78651
T78651
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
